Have you heard?? ACTG 5279: One-month TB prophylaxis as effective as nine-month regimen for people living with HIV
Community Partners and the Community Research Advisors Group (CRAG) will host a webinar on 10 July 2018 to present results from the ACTG 5279/BRIEF-TB trial, a phase III study that evaluated the safety and efficacy of a one-month regimen for preventing TB (1HP) in people with HIV.
The study favorably compared 1HP (which involves taking rifapentine and isoniazid daily for one month) to the longer 9-month regimen of daily isoniazid (isoniazid preventive therapy or IPT).
This is a landmark study that promises to shorten preventive therapy for people with HIV and improve its acceptability. The principal investigators of the study will present the trial results and discuss implications for the field. There will also be a discussion of how activists and community members can work to improve the availability, accessibility, and affordability of the regimen.
For more information about the webinar and to register, click here.